Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Elaine Lam

Concepts (314)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Renal Cell
37
2026
230
7.010
 Why?
Kidney Neoplasms
40
2026
413
6.550
 Why?
Prostatic Neoplasms
13
2023
978
2.820
 Why?
Neoplasms, Germ Cell and Embryonal
3
2023
76
1.420
 Why?
Antineoplastic Agents
15
2024
2214
1.280
 Why?
Prostate-Specific Antigen
4
2023
161
1.140
 Why?
Antibodies, Monoclonal, Humanized
12
2025
992
1.110
 Why?
Protein Kinase Inhibitors
12
2026
981
1.020
 Why?
Antineoplastic Combined Chemotherapy Protocols
15
2025
1963
0.990
 Why?
Testicular Neoplasms
3
2023
111
0.900
 Why?
Neoplasms, Unknown Primary
1
2025
20
0.890
 Why?
Neoplasms
10
2023
2906
0.890
 Why?
Antineoplastic Agents, Immunological
2
2025
198
0.830
 Why?
Carcinoma, Transitional Cell
4
2025
68
0.790
 Why?
Seminoma
2
2021
20
0.770
 Why?
Carcinoma, Medullary
2
2013
16
0.710
 Why?
Aged
37
2026
26153
0.680
 Why?
Retroperitoneal Neoplasms
1
2021
28
0.670
 Why?
Urinary Bladder Neoplasms
4
2025
258
0.650
 Why?
Male
60
2026
72842
0.650
 Why?
Pyridines
6
2026
609
0.640
 Why?
Pneumocystis carinii
1
2020
12
0.630
 Why?
Teratoma
1
2021
124
0.620
 Why?
Carcinoma, Squamous Cell
1
2025
641
0.620
 Why?
Spinal Cord Compression
1
2020
24
0.620
 Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2020
43
0.620
 Why?
Pneumonia, Pneumocystis
1
2020
34
0.610
 Why?
Euterpe
1
2018
4
0.570
 Why?
Humans
87
2026
145474
0.570
 Why?
TWEAK Receptor
1
2017
6
0.530
 Why?
Middle Aged
39
2026
36215
0.530
 Why?
Prednisone
3
2020
224
0.530
 Why?
Pyrazoles
3
2022
517
0.520
 Why?
Anilides
5
2023
84
0.510
 Why?
Abiraterone Acetate
1
2017
15
0.510
 Why?
Sulfonamides
3
2015
583
0.500
 Why?
Biomarkers, Tumor
6
2025
1321
0.500
 Why?
Adrenal Cortex Hormones
1
2020
484
0.490
 Why?
Plant Extracts
1
2018
188
0.490
 Why?
Aged, 80 and over
17
2025
8333
0.470
 Why?
Neoplasm Metastasis
9
2020
688
0.460
 Why?
Antineoplastic Agents, Hormonal
2
2015
193
0.460
 Why?
Neoplasm Recurrence, Local
3
2023
1149
0.450
 Why?
Carcinoma, Papillary
1
2015
77
0.440
 Why?
Brain Neoplasms
2
2021
1329
0.430
 Why?
Paclitaxel
3
2022
257
0.420
 Why?
Everolimus
2
2025
112
0.420
 Why?
Patient Reported Outcome Measures
4
2025
497
0.410
 Why?
Prostatic Neoplasms, Castration-Resistant
3
2022
53
0.410
 Why?
Interleukin-2
2
2014
440
0.410
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.400
 Why?
Antibodies, Monoclonal
2
2017
1505
0.380
 Why?
Urologic Neoplasms
2
2025
31
0.370
 Why?
Nephrectomy
4
2024
163
0.360
 Why?
Treatment Outcome
17
2025
11772
0.360
 Why?
Retrospective Studies
18
2024
17291
0.350
 Why?
Epothilones
1
2011
2
0.350
 Why?
Angiomyolipoma
1
2011
21
0.340
 Why?
Androgen Antagonists
3
2020
91
0.340
 Why?
Carcinoma, Non-Small-Cell Lung
3
2025
1189
0.340
 Why?
Deoxycytidine
2
2010
220
0.330
 Why?
Multicenter Studies as Topic
1
2012
412
0.320
 Why?
Benzenesulfonates
1
2010
23
0.320
 Why?
Suramin
1
2010
8
0.310
 Why?
Adult
27
2025
40777
0.310
 Why?
Lung Neoplasms
4
2025
2664
0.310
 Why?
Maximum Tolerated Dose
6
2022
210
0.290
 Why?
Radiosurgery
3
2019
399
0.280
 Why?
Female
35
2026
78844
0.280
 Why?
Immunotherapy
5
2024
666
0.270
 Why?
Indenes
2
2025
6
0.270
 Why?
Fluorouracil
1
2008
231
0.260
 Why?
Disease Progression
3
2021
2864
0.260
 Why?
Bone Neoplasms
2
2023
259
0.260
 Why?
Quinazolines
1
2008
266
0.250
 Why?
Chemotherapy, Adjuvant
3
2013
423
0.250
 Why?
Neoplasm Staging
7
2017
1471
0.240
 Why?
Practice Guidelines as Topic
4
2024
1581
0.240
 Why?
Platinum
2
2024
48
0.240
 Why?
Drug Administration Schedule
3
2021
782
0.230
 Why?
Thyroid Neoplasms
1
2010
350
0.230
 Why?
Proto-Oncogene Proteins c-kit
1
2026
72
0.230
 Why?
Sulfones
2
2017
127
0.220
 Why?
B7-H1 Antigen
2
2025
244
0.220
 Why?
Microsatellite Instability
1
2025
55
0.220
 Why?
Prognosis
5
2023
4316
0.220
 Why?
Phenylurea Compounds
4
2016
119
0.220
 Why?
Benzoxazoles
2
2022
20
0.200
 Why?
Melanoma
2
2025
759
0.200
 Why?
Ipilimumab
2
2021
40
0.200
 Why?
Taste
1
2026
238
0.200
 Why?
Taxoids
2
2017
114
0.200
 Why?
Taste Buds
1
2026
214
0.190
 Why?
Multiple Sclerosis
2
2019
489
0.180
 Why?
Bevacizumab
2
2020
168
0.180
 Why?
Kaplan-Meier Estimate
5
2024
969
0.180
 Why?
Quantitative Trait Loci
1
2024
378
0.170
 Why?
Pyrimidines
3
2022
530
0.170
 Why?
Mastectomy
1
2023
184
0.170
 Why?
Remission, Spontaneous
1
2021
39
0.170
 Why?
Administration, Oral
4
2024
866
0.170
 Why?
Biliary Tract Neoplasms
1
2021
31
0.160
 Why?
Celecoxib
2
2012
42
0.160
 Why?
Neoplasm, Residual
1
2021
143
0.160
 Why?
Carboplatin
1
2021
162
0.160
 Why?
Phosphatidylinositol 3-Kinases
1
2022
382
0.160
 Why?
Syndrome
1
2021
381
0.160
 Why?
Bariatric Surgery
1
2024
252
0.160
 Why?
Proto-Oncogene Proteins c-akt
1
2022
440
0.160
 Why?
Combined Modality Therapy
4
2019
1266
0.160
 Why?
Quality of Life
2
2025
3204
0.160
 Why?
Genomics
1
2025
825
0.150
 Why?
Azepines
1
2020
105
0.150
 Why?
Cancer Care Facilities
1
2020
48
0.150
 Why?
Antiemetics
1
2020
51
0.150
 Why?
Homologous Recombination
1
2019
37
0.150
 Why?
Fatal Outcome
1
2020
305
0.150
 Why?
Thrombosis
1
2023
400
0.150
 Why?
TOR Serine-Threonine Kinases
1
2022
454
0.150
 Why?
Morpholines
1
2020
130
0.150
 Why?
MAP Kinase Kinase Kinases
1
2019
70
0.140
 Why?
Pharyngitis
1
2019
25
0.140
 Why?
Streptococcus
1
2019
29
0.140
 Why?
Disease-Free Survival
4
2016
767
0.140
 Why?
Fruit and Vegetable Juices
1
2018
21
0.140
 Why?
Drug Hypersensitivity
1
2020
90
0.140
 Why?
Anti-Bacterial Agents
2
2020
1923
0.140
 Why?
Diagnosis, Computer-Assisted
1
2019
92
0.140
 Why?
Feedback
1
2019
180
0.140
 Why?
Mutation
2
2025
4075
0.140
 Why?
Indans
1
2017
13
0.130
 Why?
Neoplastic Cells, Circulating
2
2016
81
0.130
 Why?
Cost-Benefit Analysis
1
2021
639
0.130
 Why?
Interferon beta-1b
1
2017
2
0.130
 Why?
Pancreatic Neoplasms
1
2026
928
0.130
 Why?
Genome-Wide Association Study
1
2024
1407
0.130
 Why?
Proton Therapy
1
2017
15
0.130
 Why?
Niacinamide
3
2016
104
0.130
 Why?
Liver Neoplasms
1
2023
776
0.130
 Why?
Erythrocytes, Abnormal
1
2016
14
0.120
 Why?
Polymorphism, Single Nucleotide
1
2024
2158
0.120
 Why?
Dose-Response Relationship, Drug
3
2022
2028
0.120
 Why?
Hematologic Diseases
1
2016
66
0.120
 Why?
Multiple Sclerosis, Relapsing-Remitting
1
2017
83
0.120
 Why?
DNA Damage
1
2019
437
0.120
 Why?
Streptococcal Infections
1
2019
171
0.120
 Why?
Cell Line, Tumor
3
2020
3542
0.120
 Why?
Oncolytic Virotherapy
1
2015
13
0.120
 Why?
Neoadjuvant Therapy
2
2023
465
0.120
 Why?
Problem Solving
1
2017
156
0.120
 Why?
Indazoles
2
2015
85
0.120
 Why?
Mammalian orthoreovirus 3
1
2015
38
0.120
 Why?
Autoimmune Diseases
1
2020
468
0.110
 Why?
Angiopoietin-1
1
2015
12
0.110
 Why?
Angiopoietin-2
1
2015
15
0.110
 Why?
Genetic Predisposition to Disease
1
2024
2378
0.110
 Why?
Pyrroles
1
2016
220
0.110
 Why?
Fatigue
2
2022
364
0.110
 Why?
Receptor, IGF Type 1
1
2015
64
0.110
 Why?
Imidazoles
2
2015
247
0.110
 Why?
Kidney Glomerulus
1
2015
125
0.110
 Why?
Radiation Tolerance
1
2015
103
0.110
 Why?
Nanoparticles
1
2021
517
0.110
 Why?
Proto-Oncogene Proteins p21(ras)
1
2015
254
0.110
 Why?
Soft Tissue Neoplasms
1
2015
131
0.100
 Why?
Severity of Illness Index
2
2019
2930
0.100
 Why?
Magnetic Resonance Imaging
2
2021
3904
0.100
 Why?
Prefrontal Cortex
1
2017
334
0.100
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
109
0.100
 Why?
Prostatectomy
1
2013
94
0.100
 Why?
Patient Satisfaction
1
2017
709
0.090
 Why?
Glycine
1
2014
186
0.090
 Why?
Indoles
1
2016
507
0.090
 Why?
Cohort Studies
5
2021
6013
0.090
 Why?
Recombinant Fusion Proteins
1
2015
666
0.090
 Why?
Quinolines
1
2013
190
0.090
 Why?
Tubulin Modulators
1
2011
11
0.090
 Why?
Glomerular Filtration Rate
1
2015
765
0.090
 Why?
Metabolic Clearance Rate
1
2011
115
0.090
 Why?
Emotions
1
2017
574
0.090
 Why?
Algorithms
1
2019
1845
0.080
 Why?
Arthralgia
1
2011
61
0.080
 Why?
Area Under Curve
1
2011
331
0.080
 Why?
Clinical Trials as Topic
1
2015
1061
0.080
 Why?
Peripheral Nervous System Diseases
1
2011
134
0.080
 Why?
Diarrhea
1
2011
193
0.080
 Why?
Breast Neoplasms
1
2023
2382
0.080
 Why?
Mechanistic Target of Rapamycin Complex 1
2
2022
138
0.080
 Why?
Molecular Structure
1
2011
486
0.080
 Why?
Proto-Oncogene Proteins c-ret
1
2010
41
0.080
 Why?
Biopsy
1
2013
1082
0.080
 Why?
Survival Rate
3
2020
2090
0.080
 Why?
Nomograms
1
2010
59
0.070
 Why?
Decision Making
1
2017
977
0.070
 Why?
Immunohistochemistry
1
2013
1716
0.070
 Why?
Tomography, X-Ray Computed
3
2022
2769
0.070
 Why?
Radiotherapy, Adjuvant
1
2010
222
0.070
 Why?
Drug Synergism
1
2010
354
0.070
 Why?
Capecitabine
1
2008
56
0.070
 Why?
Infusions, Intravenous
1
2010
428
0.070
 Why?
Adenine
2
2022
339
0.070
 Why?
Positron-Emission Tomography
1
2010
343
0.070
 Why?
Proteinuria
1
2008
104
0.070
 Why?
Hypertension, Pregnancy-Induced
1
2008
69
0.060
 Why?
Dysgeusia
1
2026
5
0.060
 Why?
Follow-Up Studies
3
2020
5423
0.060
 Why?
Young Adult
4
2024
14218
0.060
 Why?
Creatinine
1
2008
515
0.060
 Why?
Risk
1
2008
919
0.060
 Why?
Optical Illusions
1
2005
2
0.060
 Why?
Urothelium
1
2025
33
0.050
 Why?
Von Hippel-Lindau Tumor Suppressor Protein
1
2024
19
0.050
 Why?
Risk Factors
2
2020
10885
0.050
 Why?
Cell Lineage
1
2026
377
0.050
 Why?
Cytoreduction Surgical Procedures
1
2024
69
0.050
 Why?
Prospective Studies
3
2021
8057
0.050
 Why?
Mastectomy, Segmental
1
2023
107
0.050
 Why?
Adjuvants, Immunologic
1
2024
243
0.050
 Why?
RNA Interference
1
2024
475
0.050
 Why?
Cardiovascular Diseases
1
2014
2187
0.040
 Why?
Disease Management
2
2017
653
0.040
 Why?
RNA, Small Interfering
1
2024
637
0.040
 Why?
Cisplatin
1
2023
345
0.040
 Why?
Nephritis, Interstitial
1
2020
11
0.040
 Why?
International Agencies
1
2020
30
0.040
 Why?
Drug Evaluation
1
2020
79
0.040
 Why?
Aurora Kinase A
1
2020
61
0.040
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.040
 Why?
Lymphocytes
1
2022
376
0.040
 Why?
Nausea
1
2020
112
0.040
 Why?
Analysis of Variance
2
2017
1300
0.040
 Why?
Hong Kong
1
2019
7
0.040
 Why?
Vomiting
1
2020
131
0.040
 Why?
Lymphatic Metastasis
1
2020
331
0.040
 Why?
Time Factors
1
2010
7123
0.040
 Why?
Sex Factors
1
2025
2105
0.040
 Why?
Mice, Knockout
1
2026
3124
0.040
 Why?
Hospitals
1
2023
732
0.040
 Why?
Medical Oncology
1
2022
339
0.040
 Why?
DNA-Binding Proteins
1
2026
1480
0.030
 Why?
Cell Differentiation
1
2026
2046
0.030
 Why?
Central Nervous System
1
2020
282
0.030
 Why?
Transcription Factors
1
2026
1734
0.030
 Why?
Genetic Testing
1
2020
480
0.030
 Why?
Retreatment
1
2017
79
0.030
 Why?
Databases, Factual
1
2023
1490
0.030
 Why?
Drug Therapy, Combination
1
2020
1044
0.030
 Why?
United States
2
2017
16098
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
54
0.030
 Why?
Receptor Protein-Tyrosine Kinases
1
2019
231
0.030
 Why?
Xenograft Model Antitumor Assays
1
2020
934
0.030
 Why?
Erythrocyte Indices
1
2016
33
0.030
 Why?
Academic Medical Centers
1
2020
554
0.030
 Why?
Antimicrobial Stewardship
1
2019
130
0.030
 Why?
Anti-Inflammatory Agents
1
2020
477
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2019
261
0.030
 Why?
Case-Control Studies
1
2024
3623
0.030
 Why?
Neutrophils
1
2022
1124
0.030
 Why?
Clinical Decision-Making
1
2019
363
0.030
 Why?
Mice
2
2026
18329
0.030
 Why?
Acute Disease
1
2019
1036
0.030
 Why?
Thoracic Neoplasms
1
2015
39
0.030
 Why?
Abdominal Neoplasms
1
2015
47
0.030
 Why?
Tosyl Compounds
1
2015
17
0.030
 Why?
Antibodies, Neoplasm
1
2015
34
0.030
 Why?
Kidney Function Tests
1
2015
156
0.030
 Why?
Reaction Time
1
2017
433
0.030
 Why?
Angiogenesis Inhibitors
1
2016
238
0.030
 Why?
Neoplasm Grading
1
2015
310
0.030
 Why?
Craniocerebral Trauma
1
2017
178
0.030
 Why?
Radiotherapy
1
2015
204
0.030
 Why?
Organ Size
1
2015
461
0.030
 Why?
Postoperative Period
1
2015
351
0.030
 Why?
Drug Resistance, Neoplasm
1
2020
881
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
149
0.030
 Why?
Demography
1
2015
282
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
142
0.030
 Why?
STAT5 Transcription Factor
1
2014
50
0.030
 Why?
Animals
3
2026
38030
0.030
 Why?
Nitriles
1
2015
207
0.030
 Why?
Recurrence
1
2017
1138
0.020
 Why?
Drug Interactions
1
2015
405
0.020
 Why?
Gonadotropin-Releasing Hormone
1
2015
217
0.020
 Why?
Medication Adherence
1
2017
540
0.020
 Why?
ErbB Receptors
1
2015
635
0.020
 Why?
Cell Survival
1
2015
1100
0.020
 Why?
Longitudinal Studies
1
2020
2953
0.020
 Why?
Proportional Hazards Models
1
2015
1327
0.020
 Why?
Neuropsychological Tests
1
2017
1134
0.020
 Why?
Double-Blind Method
1
2016
2062
0.020
 Why?
T-Lymphocytes, Regulatory
1
2014
409
0.020
 Why?
Molecular Targeted Therapy
1
2014
439
0.020
 Why?
Proto-Oncogene Proteins
1
2014
624
0.020
 Why?
Enzyme Inhibitors
1
2014
820
0.020
 Why?
Biomarkers
1
2022
4295
0.020
 Why?
Cell Cycle Proteins
1
2014
630
0.020
 Why?
Logistic Models
1
2015
2134
0.020
 Why?
Reagent Strips
1
2008
8
0.020
 Why?
Primary Health Care
1
2019
1735
0.020
 Why?
Urinalysis
1
2008
83
0.020
 Why?
Albuminuria
1
2008
189
0.020
 Why?
Diagnostic Tests, Routine
1
2008
107
0.020
 Why?
Vision, Monocular
1
2005
4
0.010
 Why?
Psychophysics
1
2005
15
0.010
 Why?
Eye Enucleation
1
2005
14
0.010
 Why?
Vision, Binocular
1
2005
47
0.010
 Why?
Orientation
1
2005
50
0.010
 Why?
Adolescent
2
2020
22529
0.010
 Why?
Pattern Recognition, Visual
1
2005
104
0.010
 Why?
Photic Stimulation
1
2005
263
0.010
 Why?
Sensitivity and Specificity
1
2008
1997
0.010
 Why?
Signal Transduction
1
2014
5216
0.010
 Why?
Pregnancy
1
2008
7202
0.010
 Why?
Child
1
2005
22707
0.000
 Why?
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (314) concept(s)
_
Co-Authors Expand Description
See all (51) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)